Qiagen N.v. · NYSE:QGEN
Qiagen — Exane MedTech CEO Conference (November 2020)
23 slides from Qiagen's conference presentation, Nov 5, 2020
Slide 1: Investor Handout Q4 2020
Investor Handout Q4 2020 Sample to Insight
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: This presentation contains both historical and forward-looking governments, global or regional economic developments, weather or transportation delays, statements. All statements other than statements of historical fact are, or may b
Slide 3: Agenda
Agenda Introduction John Gilardi VP Corp Communications and IR Business and financial update Thierry Bernard Chief Executive Officer Roland Sackers Chief Financial Officer Q&A session Sample to Insight Investor Handout Q4 2020 3
Slide 4: Overview
Overview 1 Q3 2020: Exceeded sales outlook and at high end of range for Q3 and 9M net sales Q3 and 9M adjusted EPS(1) adjusted diluted EPS (In $ millions, at actual rates) (In $ per share) • $483.8 m net sales (+26% actual, +26% CER vs. ~16-21% CER outlook) +18% CER +53% CER • $0.58 adj. diluted EPS
Slide 5: Q3 and 9M 2020: Financial review
Q3 and 9M 2020: Financial review Third quarter First nine months (In $ millions, unless indicated) (Diluted EPS in $ per share) 2020 2019 Change 2020 2019 Change Net sales(1) 483.8 382.7 26% / 26% CER 1,299.1 1,113.0 17% / 18% CER Operating income (loss) 44.5 (207.5) NM 230.5 (106.1) NM Adjusted ope
Slide 6: Q3 and 9M 2020: Sales by product type, customer class and region
Q3 and 9M 2020: Sales by product type, customer class and region Q3 2020 net sales: $483.8 million 9M 2020 net sales: $1.3 billion Sales % % CER % Sales % % CER % Sales by product type (In $ m) change change of sales (In $ m) change change of sales Consumables and related revenues $420 23% 22% 87% $
Slide 7: Directing investments to capture key growth opportunities
Directing investments to capture key growth opportunities Life Sciences Molecular Diagnostics Academic / Applied Testing Pillars of growth Clinical healthcare Pharma Sample Technologies QuantiFERON NeuMoDx QIAstat-Dx Five pillars of growth QIAcuity digital PCR NEW Planned Sample to Insight Investor
Slide 8: Building a comprehensive portfolio of COVID-19 testing solutions
Building a comprehensive portfolio of COVID-19 testing solutions RNA sample PCR testing OEM components Antigen and technologies solutions for other suppliers antibody testing Third-party manufacturing • QIAreach SARS- Coming • Manual extraction kits • QIAstat-Dx: in Q4 CoV-2 Antigen 2020 • Automatio
Slide 9: COVID-19 testing solutions: Serving evolving demand trends as pandemic progresses
COVID-19 testing solutions: Serving evolving demand trends as pandemic progresses Capacity Q3 2020 sales: COVID-related product groups status COVID-19 product groups RNA sample technologies • Sufficient manual RNA extraction capacity, but reduced demand (ongoing demand shift from ~70% of extractions
Slide 10: Q4 and FY 2020: Outlook and assumptions
Q4 and FY 2020: Outlook and assumptions (As of October 28, 2020) Q4 2020 outlook FY 2020 outlook ~+24-27% CER ~+20% CER Net sales (Prior year: $413.5 m) (Prior year: $1,526.4 m) ~$0.58-0.60 CER ~$2.07-2.09 CER Adjusted EPS(1) (Prior year: $0.48) (Prior year: $1.43) Adjustments to operating income (i
Slide 11: Summary
Summary • Outstanding Q3 2020 results: +26% CER sales growth exceeds outlook and adjusted diluted EPS rises 61% to $0.58 CER, top end of range • Significant contributions from COVID-19 solutions – leaving no country behind • QIAGEN is COVID-19 relevant but not COVID-19 dependent: Sharpening focus on
Slide 12: Appendix
George Mason University in Fairfax, Virginia Appendix Sample to Insight
Slide 13: Q3 2020: Consolidated Statements of Income (unaudited)
Q3 2020: Consolidated Statements of Income (unaudited) Three months ended Three months ended (In $ thousands, except share data) September 30, 2020 September 30, 2019 Net sales 483,763 382,686 Cost of sales: Cost of sales 147,297 109,648 Acquisition-related intangible amortization 15,692 18,096 Tota
Slide 14: 9M 2020: Consolidated Statements of Income (unaudited)
9M 2020: Consolidated Statements of Income (unaudited) Nine months ended Nine months ended (In $ thousands, except share data) September 30, 2020 September 30, 2019 Net sales 1,299,112 1,112,952 Cost of sales: Cost of sales 394,084 331,953 Acquisition-related intangible amortization 45,746 55,302 To
Slide 15: Q3 and 9M 2020: Reconciliation adjusted results
Q3 and 9M 2020: Reconciliation adjusted results Net Gross Operating Pretax Income Tax Net Diluted In $ millions (Except EPS) profit income tax rate EPS (Unaudited) sales Income Income Third quarter 2020 Reported results 483.8 320.8 44.5 27.9 (11.0) 39% 16.9 0.07 Adjustments Business integration, acq
Slide 16: Q3 and 9M 2020: Currency impact
Q3 and 9M 2020: Currency impact Net sales Net sales Currency exposure Change (In $ millions) (CER) (As % of CER sales) (In $ millions) Third quarter 2020 U.S. dollar 229.2 229.2 48% 0.0 Euro 116.5 110.9 23% 5.6 British pound 17.1 15.4 3% 1.7 Japanese yen 15.5 16.3 3% -0.8 Other currencies 105.5 109.
Slide 17: 2020: Quarterly and full-year income statement summary
2020: Quarterly and full-year income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2020 Q2 2020 Q3 2020 Q4 2020 YTD 2020 Net sales 372.1 443.3 483.8 1,299.1 Net sales (CER) 379.0 452.4 481.3 1,312.7 Gross profit 243.5 295.0 320.8 859.3 Gross profit margin 65% 67
Slide 18: 2019: Quarterly and full-year income statement summary
2019: Quarterly and full-year income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2019 Q2 2019 Q3 2019 Q4 2019 FY 2019 Net sales 348.7 381.6 382.7 413.5 1,526.4 Gross profit 224.8 245.9 254.9 279.6 1,005.3 Gross profit margin 64% 64% 67% 68% 66% Adjusted gross
Slide 19: 2020: Total net sales overview
2020: Total net sales overview Net sales by customer class (In $ millions at actual rates / Q1 2020 Q2 2020 Q3 2020 Q4 2020 YTD 2020 change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Molecular Diagnostics 176 4% 7% 204 9% 12% 237 29% 30% 617 14%
Slide 20: Consolidated Balance Sheets
Consolidated Balance Sheets September 30, December 31, September 30, December 31, (In $ thousands, except par value) 2020 2019 (In $ thousands, except par value) 2020 2019 Assets (unaudited) Liabilities and Equity (unaudited) Current assets: Current liabilities: Current portion of long-term debt 311
Slide 21: Consolidated Statements of Cash Flows (unaudited)
Consolidated Statements of Cash Flows (unaudited) Nine months ended Nine months ended September 30, September 30, September 30, September 30, (In $ thousands) 2020 2019 (In $ thousands) 2020 2019 Cash flows from operating activities: Cash flows from financing activities: Net income (loss) 146,503 (8
Slide 22: Employees as of September 30, 2020
Employees as of September 30, 2020 Europe / Asia Pacific / Total Total Americas Middle East / Africa Japan / ROW Q3 2020 Q3 2019 Change Production 253 932 144 1,329 1,177 13% R&D 182 662 49 893 1,026 -13% Sales 562 810 801 2,173 2,081 4% Marketing 70 167 82 319 329 -3% Administration 77 372 150 599
Slide 23: Your contacts
Your contacts John Gilardi Vice President Calendar Corporate Communications and IR Phone: +49 2103 29 11711 QIAGEN Virtual Deep Dive December 8, 2020 +1 240 686 2222 Mobile: +49 152 018 11711 Q4 2020 results February 2021 E-mail: john.gilardi@qiagen.com Q1 2021 results May 2021 Phoebe Loh Share info
Qiagen — Exane MedTech CEO Conference (November 2020) on 6ix